Cancer Res Treat.  2010 Mar;42(1):1-11.

Salvage Radiotherapy for Patients with PSA Relapse Following Radical Prostatectomy: Issues and Challenges

Affiliations
  • 1Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA. choo.c@mayo.edu

Abstract

A progressively rising level of serum prostate specific antigen (PSA) after radical prostatectomy (RP) invariably indicates the recurrence of prostate cancer. The optimal management of patients with post-RP PSA relapse has remained uncertain due to a wide variability in the natural course of post-RP PSA relapse and the inability to separate a recurrent disease confined to the prostate bed from that with occult distant metastasis. Management uncertainty is further compounded by the lack of phase III clinical studies demonstrating which therapeutic approach, if any, would prolong life with no significant morbidity. Radiotherapy has been the main therapeutic modality with a curative potential for patients with post-RP PSA relapse. This review article depicts issues and challenges in the management of patients with post-RP PSA relapse, presents the literature data for the efficacy of salvage radiotherapy, either alone or in combination of androgen ablation therapy, and discusses future directions that can optimize treatment strategies.

Keyword

Salvage radiotherapy; PSA relapse; Post radical prostatectomy

MeSH Terms

Humans
Neoplasm Metastasis
Prostate
Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms
Recurrence
Uncertainty
Prostate-Specific Antigen

Reference

1. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004; 171:1393–1401. PMID: 15017184.
Article
2. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007; 178:S14–S19. PMID: 17644125.
Article
3. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 1988; 139:766–772. PMID: 2451037.
Article
4. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol. 1994; 152:1358–1368. PMID: 7523702.
Article
5. Presti JC Jr, Shinohara K, Bacchetti P, Tigrani V, Bhargava V. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology. 1998; 52:1079–1084. PMID: 9836558.
Article
6. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999; 281:1591–1597. PMID: 10235151.
Article
7. Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol. 2002; 168:110–115. PMID: 12050502.
Article
8. Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol. 2001; 166:1322–1327. PMID: 11547066.
Article
9. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002; 167:528–534. PMID: 11792912.
Article
10. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001; 165:1146–1151. PMID: 11257657.
Article
11. Iselin CE, Robertson JE, Paulson DF. Radical perineal prostatectomy: oncological outcome during a 20-year period. J Urol. 1999; 161:163–168. PMID: 10037390.
Article
12. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003; 61:365–369. PMID: 12597949.
13. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007; 177:540–545. PMID: 17222629.
Article
14. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008; 53:68–80. PMID: 17920184.
Article
15. Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract. 2004; 58:382–390. PMID: 15161124.
Article
16. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006; 24:3973–3978. PMID: 16921049.
Article
17. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004; 22:537–556. [Erratum appears in J Clin Oncol. 2004;22:3205]. PMID: 14752077.
Article
18. Ellis WJ, Vessella RL, Noteboom JL, Lange PH, Wolfert RL, Rittenhouse HG. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology. 1997; 50:573–579. PMID: 9338734.
Article
19. Doherty AP, Bower M, Smith GL, Miano R, Mannion EM, Mitchell H, et al. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival. Br J Cancer. 2000; 83:1432–1436. PMID: 11076649.
Article
20. Ornstein DK, Oh J, Herschman JD, Andriole GL. Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am. 1998; 25:591–601. PMID: 10026768.
Article
21. Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am. 1997; 24:275–282. PMID: 9126224.
Article
22. Karakiewicz PI, Eastham JA, Graefen M, Cagiannos I, Stricker PD, Klein E, et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5,831 patients. Urology. 2005; 66:1245–1250. PMID: 16360451.
Article
23. Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology. 2003; 62:866–871. PMID: 14624910.
Article
24. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009; 181:956–962. PMID: 19167731.
Article
25. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007; 25:2225–2229. PMID: 17538167.
Article
26. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005; 366:572–578. PMID: 16099293.
Article
27. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009; 27:2924–2930. PMID: 19433689.
28. Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, Sakr WA, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998; 160:1387–1391. PMID: 9751361.
Article
29. Dotan ZA, Bianco FJ Jr, Rabbani F, Eastham JA, Fearn P, Scher HI, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol. 2005; 23:1962–1968. PMID: 15774789.
Article
30. Gomez P, Manoharan M, Kim SS, Soloway MS. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int. 2004; 94:299–302. PMID: 15291855.
Article
31. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, DeKernion JB, et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol. 2004; 171:2260–2264. PMID: 15126798.
Article
32. Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003; 61:607–611. PMID: 12639656.
Article
33. Saleem MD, Sanders H, Abu El Naser M, El-Galley R. Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology. 1998; 51:283–286. PMID: 9495712.
Article
34. Connolly JA, Shinohara K, Presti JC Jr, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology. 1996; 47:225–231. PMID: 8607239.
Article
35. Shekarriz B, Upadhyay J, Wood DP Jr, Hinman J, Raasch J, Cummings GD, et al. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology. 1999; 54:1044–1048. PMID: 10604706.
Article
36. Scattoni V, Montorsi F, Picchio M, Roscigno M, Salonia A, Rigatti P, et al. Diagnosis of local recurrence after radical prostatectomy. BJU Int. 2004; 93:680–688. PMID: 15009088.
Article
37. Naya Y, Okihara K, Evans RB, Babaian RJ. Efficacy of prostatic fossa biopsy in detecting local recurrence after radical prostatectomy. Urology. 2005; 66:350–355. PMID: 16040095.
Article
38. Deliveliotis C, Manousakas T, Chrisofos M, Skolarikos A, Delis A, Dimopoulos C. Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy. World J Urol. 2007; 25:309–313. PMID: 17440730.
Article
39. Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol. 2001; 166:111–115. PMID: 11435834.
Article
40. Sella T, Schwartz LH, Swindle PW, Onyebuchi CN, Scardino PT, Scher HI, et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology. 2004; 231:379–385. PMID: 15064390.
Article
41. Miralbell R, Vees H, Lozano J, Khan H, Molla M, Hidalgo A, et al. Endorectal MRI assessment of local relapse after surgery for prostate cancer: a model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys. 2007; 67:356–361. PMID: 17236961.
Article
42. Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M, et al. Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol. 2008; 54:589–600. PMID: 18226441.
Article
43. Hinkle GH, Burgers JK, Neal CE, Texter JH, Kahn D, Williams RD, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer. 1998; 83:739–747. PMID: 9708939.
Article
44. Raj GV, Partin AW, Polascik TJ. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer. 2002; 94:987–996. PMID: 11920467.
Article
45. Petronis JD, Regan F, Lin K. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med. 1998; 23:672–677. PMID: 9790041.
Article
46. Elgamal AA, Troychak MJ, Murphy GP. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate. 1998; 37:261–269. PMID: 9831223.
Article
47. Nagda SN, Mohideen N, Lo SS, Khan U, Dillehay G, Wagner R, et al. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2007; 67:834–840. PMID: 17293236.
Article
48. Koontz BF, Mouraviev V, Johnson JL, Mayes J, Chen SH, Wong TZ, et al. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 71:358–361. PMID: 18164863.
Article
49. Thomas CT, Bradshaw PT, Pollock BH, Montie JE, Taylor JMG, Thames HD, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol. 2003; 21:1715–1721. PMID: 12721246.
Article
50. Rinnab L, Simon J, Hautmann RE, Cronauer MV, Hohl K, Buck AK, et al. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol. 2009; 27:619–625. PMID: 19234708.
Article
51. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009; 50:1394–1400. [Erratum appears in J Nucl Med. 2009; 50:1578]. PMID: 19690023.
Article
52. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvicretroperitoneal lymphadenectomy. Eur Urol. 2007; 52:423–429. PMID: 17397992.
Article
53. Schilling D, Schlemmer HP, Wagner PH, Bottcher P, Merseburger AS, Aschoff P, et al. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int. 2008; 102:446–451. PMID: 18410442.
54. Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int. 2007; 99:1415–1420. PMID: 17428249.
55. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005; 294:433–439. PMID: 16046649.
Article
56. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004; 171:1141–1147. [Reprint in J Urol. 2008;179(5 Suppl):S53-9; PMID: 18405753]. PMID: 14767288.
Article
57. Shipley WU, Desilvio M, Pilepich MV, Roach M 3rd, Wolkov HB, Sause WT, et al. Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. Int J Radiat Oncol Biol Phys. 2006; 64:1162. 1167. [Erratum appears in Int J Radiat Oncol Biol Phys. 2006;65:313]. PMID: 16427211.
Article
58. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299:2760–2769. PMID: 18560003.
Article
59. Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Blute ML. Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol. 2009; 182:2708–2714. PMID: 19836762.
Article
60. Choo R, Hruby G, Hong J, Bahk E, Hong E, Danjoux C, et al. (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2002; 53:269–276. PMID: 12023129.
Article
61. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007; 25:2035–2041. [Erratum appears in J Clin Oncol. 2007;25:4153]. PMID: 17513807.
Article
62. Choo R, Morton G, Danjoux C, Hong E, Szumacher E, DeBoer G. Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate carcinoma after surgery. Radiother Oncol. 2005; 74:163–167. PMID: 15734204.
Article
63. Macdonald OK, Schild SE, Vora SA, Andrews PE, Ferrigni RG, Novicki DE, et al. Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2004; 58:1530–1535. PMID: 15050333.
Article
64. Ray GR, Bagshaw MA, Freiha F. External beam radiation salvage for residual or recurrent local tumor following radical prostatectomy. J Urol. 1984; 132:926–930. PMID: 6436511.
Article
65. Rosen EM, Cassady JR, Connolly J, Chaffey JT. Radiotherapy for localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 1984; 10:2201–2210. PMID: 6439698.
Article
66. Loeb S, Roehl KA, Viprakasit DP, Catalona WJ. Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. Eur Urol. 2008; 54:88–94. PMID: 18400368.
Article
67. De Meerleer G, Fonteyne V, Meersschout S, Van den Broecke C, Villeirs G, Lumen N, et al. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiother Oncol. 2008; 89:205–213. PMID: 18771809.
Article
68. Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol. 2006; 176:985–990. PMID: 16890677.
Article
69. Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000; 163:845–850. PMID: 10687990.
Article
70. Neuhof D, Hentschel T, Bischof M, Sroka-Perez G, Hohenfellner M, Debus J. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int J Radiat Oncol Biol Phys. 2007; 67:1411–1417. PMID: 17275204.
Article
71. Wiegel T, Lohm G, Bottke D, Hocht S, Miller K, Siegmann A, et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. Int J Radiat Oncol Biol Phys. 2009; 73:1009–1016. PMID: 18963539.
Article
72. Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2001; 19:1030–1039. [Erratum appears in J Clin Oncol. 2001;19:2109]. PMID: 11181666.
Article
73. Pazona JF, Han M, Hawkins SA, Roehl KA, Catalona WJ. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol. 2005; 174:1282–1286. PMID: 16145393.
Article
74. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004; 291:1325–1332. PMID: 15026399.
Article
75. Maier J, Forman J, Tekyi-Mensah S, Bolton S, Patel R, Pontes JE. Salvage radiation for a rising PSA following radical prostatectomy. Urologic Oncology. 2004; 22:50–56. PMID: 14969805.
Article
76. King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2008; 71:23–27. PMID: 18207668.
Article
77. Moreira DM, Jayachandran J, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, et al. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database. BJU Int. 2009; 104:1452–1456. PMID: 19466946.
Article
78. MacDonald OK, Schild SE, Vora S, Andrews PE, Ferrigni RG, Novicki DE, et al. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ? Urology. 2004; 64:760–764. PMID: 15491716.
Article
79. Song DY, Thompson TL, Ramakrishnan V, Harrison R, Bhavsar N, Onaodowan O, et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology. 2002; 60:281–287. PMID: 12137827.
Article
80. Macdonald OK, Schild SE, Vora SA, Andrews PE, Ferrigni RG, Novicki DE, et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J Urol. 2003; 170:1833–1837. PMID: 14532786.
Article
81. Catton C, Gospodarowicz M, Warde P, Panzarella T, Catton P, McLean M, et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2001; 59:51–60. PMID: 11295206.
Article
82. Quero L, Mongiat-Artus P, Ravery V, Maylin C, Desgrandchamps F, Hennequin C. Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience. BMC Cancer. 2008; 8:26. PMID: 18230130.
Article
83. Sasaki T, Nakamura K, Shioyama Y, Ohga S, Toba T, Urashima Y, et al. Low preradiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer. Anticancer Res. 2006; 26:2367–2374. PMID: 16821618.
84. Symon Z, Kundel Y, Sadetzki S, Oberman B, Ramon J, Laufer M, et al. Radiation rescue for biochemical failure after surgery for prostate cancer: predictive parameters and an assessment of contemporary predictive models. Am J Clin Oncol. 2006; 29:446–450. PMID: 17023777.
85. King CR, Kapp DS. Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys. 2008; 71:346–350. PMID: 18234451.
Article
86. Bernard JR Jr, Buskirk SJ, Heckman MG, Diehl NN, Ko SJ, Macdonald OK, et al. Salvage Radiotherapy for Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer: Dose-Response Analysis. Int J Radiat Oncol Biol Phys. 2010; 76:735–740. PMID: 19464818.
Article
87. Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 68:1417–1423. PMID: 17418972.
Article
88. Peterson JL, Buskirk SJ, Heckman MG, Crook JE, Ko SJ, Wehle MJ, et al. Late toxicity after postprostatectomy salvage radiation therapy. Radiother Oncol. 2009; 93:203–206. PMID: 19766337.
Article
89. Pearse M, Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, et al. Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2008; 72:792–798. PMID: 18707818.
Article
90. Choo R, Danjoux C, Gardner S, Morton G, Szumacher E, Loblaw DA, et al. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse. Int J Radiat Oncol Biol Phys. 2009; 75:983–989. PMID: 19409726.
Article
91. Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol. 2003; 21:483–489. PMID: 12560439.
Article
92. Tiguert R, Rigaud J, Lacombe L, Laverdiere J, Fradet Y. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J Urol. 2003; 170:447–450. PMID: 12853796.
Article
93. King CR, Presti JC Jr, Gill H, Brooks J, Hancock SL. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys. 2004; 59:341–347. PMID: 15145146.
Article
94. Taylor N, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, Pollack A. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 56:755–763. PMID: 12788182.
Article
95. Yokomizo A, Kawamoto H, Nihei K, Ishizuka N, Kakehi Y, Tobisu KI, et al. Randomized controlled trial to evaluate radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401. Jpn J Clin Oncol. 2005; 35:34–36. PMID: 15681602.
Article
96. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol. 2004; 172:2244–2248. PMID: 15538240.
Article
97. Brooks JP, Albert PS, Wilder RB, Gant DA, McLeod DG, Poggi MM. Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors. J Urol. 2005; 174:2204–2208. PMID: 16280764.
Article
98. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int J Radiat Oncol Biol Phys. 2000; 48:369–375. PMID: 10974449.
Article
99. Peyromaure M, Allouch M, Eschwege F, Verpillat P, Debre B, Zerbib M. Salvage radiotherapy for biochemical recurrence after radical prostatectomy: a study of 62 patients. Urology. 2003; 62:503–507. PMID: 12946755.
Article
100. Chawla AK, Thakral HK, Zietman AL, Shipley WU. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. Urology. 2002; 59:726–731. PMID: 11992848.
Article
101. De la Taille A, Flam TA, Thiounn N, Pontvert D, Saighi D, Zerbib M, et al. Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy. BJU Int. 2002; 90:887–892. PMID: 12460351.
Article
102. Liauw SL, Webster WS, Pistenmaa DA, Roehrborn CG. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology. 2003; 61:1204–1210. PMID: 12809898.
Article
103. Tomita N, Kodaira T, Furutani K, Tachibana H, Nakahara R, Mizoguchi N, et al. Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy. J Cancer Res Clin Oncol. 2009; 135:1561–1567. PMID: 19479278.
Article
104. Delongchamps NB, Zerbib M, Mejean A, Rouach Y, Debre B, Peyromaure M. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence. Can J Urol. 2009; 16:4813–4819. PMID: 19796456.
105. Jacinto AA, Fede AB, Fagundes LA, Salvajoli JV, Castilho MS, Viani GA, et al. Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy. Radiat Oncol. 2007; 2:8. PMID: 17316430.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr